Immunaeon is a Buffalo-based patient advocacy organization that provides educational resources for patients and their families. We also are working to build an infrastructure to store a person’s immune system for future use against potentially life-threatening illnesses. Through patient outreach and engagement, we empower patients to understand their clinical results and make the best treatment decisions possible.
At Immunaeon, we believe that the future for immunotherapy is bright. Our mission to help people leverage life-saving medical sciences for their lifetime—whether it’s bringing a healthier immune system to a cancer patient today, or implementing immunotherapies that will prevent different diseases in the future. At Immunaeon, we are connecting today’s science to tomorrows cures.
Adam Utley, PhD, is our Founder and Chief Patient Advocate. Adam completed his PhD in Tumor Immunology at Roswell Park Comprehensive Cancer Center. His insight into the development of immune cell-based therapies led him to found the company in 2016, even before the first cell-based therapy (Kymriah CAR-T cell therapy) was approved by the FDA in 2017. His scientific career has focused on B and T cell function, as well as how the dysregulation of immune cells leads to cancer progression. He has been invited to speak at both national and international conferences and his work has been published in several high tier journals (Blood, Nature Communications, Cell Reports, Journal of Immunology). He is a current member of the American Association of Immunologists and the American Society of Hematology.
Dan Rera, COO, received his Master’s in Economics and MBA from UB. A former Vice-President of Treasury at M&T Bank, his experience in healthcare, banking, and insurance, as well as his startup experience working in the financial arm of ACV Auctions, gives him the insight and perspective to make Immunaeon a primary portal for patient education and engagement.
Tom White, our Chief Medical Officer, is an MD with board certification in internal medicine and provides a critical bridge to patients in need of advocacy and education. He currently practices with the Buffalo Medical Group (BMG) and is one of the staff physicians for the Buffalo Bills.
Daniel Fisher, PhD, is our Chief Scientific Officer and has spent the last 2 decades in the immunology-oncology world at Roswell Park. His expertise in T cell adoptive therapy gives us cutting edge perspective on the scientific approach to analysis and storage of healthy immune cells.
Michael John, CTO, received his BA in Communication and MBA from UB. Michael has nearly 20 years of varied roles and responsibilities including managing data centers, migration to cloud storage as well as safeguarding PHI data in the cloud. This experience spans technical execution, direct leadership and managing technical risk. His education and experience bring the depth of knowledge necessary to protect patient privacy.
Joe DiNardo, Head of Growth, has worked with market leaders and start-ups across industries including: financial services (RR Donnelley, PEX), banking (JPMorgan Chase), automotive (Service King, ACV Auctions), skincare (Boots, Mario Badescu), publishing (Penguin Books, Scroll), entertainment (NBC Universal), eSports (Allstar.gg), CPG (Mattel), pharma (P&G), fitness (Rumble Boxing), and telecommunications (ATT). Having managed over $2 billion in media spend, he is deeply familiar with and has executed campaigns using all forms of digital marketing (SEO, SEM, Social, Display, Video, Email), traditional marketing (OOH, Radio, TV, Print, Direct Mail), experiential marketing (Trade Shows, Large Scale Convention Executions), influencer marketing, and next-gen marketing (Voice, AR)
Eunice Wang, MD, is the Chief of Leukemia and Director of Infusion services at Roswell Park Comprehensive Cancer Center. She is licensed in New York State and is certified by the American Board of Internal Medicine (Internal Medicine 1999; Medical Oncology, 2002; Medical Hematology, 2004). She also is an Assistant Professor, School of Medicine & Biomedical Sciences, University of Buffalo. She is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and American Society of Hematology.
Dr. Wang’s clinical research focuses on the development of early stage clinical trials for acute leukemias (AML, ALL) and myeloproliferative disorders. Her translational research interests involve the development of novel biological therapies targeting the bone marrow microenvironment for myeloid malignancies. Dr. Wang has authored/co-authored over 90 peer-reviewed articles, multiple book chapters, and editorials. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award (CCITLA) in recognition of her contributions to clinical cancer research and a Mentored Research Scholar award from the American Cancer Society. In addition to her research, Dr. Wang maintains an active clinical practice.
Jack McGowan is a project manager at Incyte Consulting as well as the Executive Director of the Buffalo Angels, a collaborative member-managed seed investment fund that evaluates investment opportunities. He specialties include: Strategic planning, business plan development, business funding, Angel Investment, ISO Quality Management Systems, NYSTAR-designated SBIR/STTR Program Regional Specialist, and he is an Innovation Engineering Process Coach. Jack has been working with Immunaeon for the past 2 years, helping to develop the strategic approach to market development at the initiation of operations.
Steve Leous has over 25 years experience in a variety of industries and functional expertise in strategic marketing, finance, and corporate development. Currently a strategic growth consultant, he previously worked at e-commerce pioneer VerticalNet, the world’s largest operator of online industry marketplaces. He launched and managed seven of them and also worked in corporate development. He has a BA from Williams College and an MBA from Northwestern University’s J.L. Kellogg School of Management.
Frank Codella is the president and CEO at Medical Accoustics. He built the company from concept to operating enterprise, securing patents in key jurisdictions around the world. He also obtained US FDA and EU (CE) regulatory clearances and built a global distribution network. Frank has been working with Immunaeon for the past year helping to develop the go-to-market strategy in WNY. He also founded MedRecovery Management which was acquired by HMS Holdings Corp (Nasdaq; HMSY) in December of 2012.